Search the Newsreel

Corteva Slides as Investors Weigh Post-Separation Risks Ahead of Earnings

Corcept Therapeutics Inc (CORT) (Q2 2026) Earnings Call Highlights: Record Revenue and ...

Corcept Therapeutics (CORT) reported strong Q2 2026 results with record revenue of $256.1 million, a 32% year-over-year increase, and net income of $43 million. The company's new oncology drug, Lifyorli, generated $47.6 million in its first quarter, and its 2026 revenue guidance was raised …

Corcept Therapeutics Incorporated (CORT) enters earnings with an 85.5% 12-week gain

The July 29 biotechnology report will test an active weekly trend against weaker Relative Strength.

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

Earnings call transcript: Corcept Therapeutics Q2 2026 revenue beat lifts stock

Corcept Therapeutics reported strong Q2 2026 results, with revenue up 32% year-over-year to $256.1 million, surpassing forecasts. The growth was driven by continued sales of Korlym and a successful debut for its new ovarian cancer drug, LIFYORLI, which generated $47.6 million. The company raised …

Corcept Therapeutics Stock Jumps Ahead Of Q2 Earnings

Corcept Therapeutics (NASDAQ: CORT) stock has surged by over 17% ahead of its Q2 2026 earnings release, driven by positive reception of its clinical pipeline, notably its newly approved drug Lifyorli. Despite a high P/E ratio and insider selling, traders are keenly anticipating updates …

Earnings Flash (CORT) Corcept Therapeutics Incorporated Reports Q2 Revenue $256.1M, vs. FactSet Est of $221.1M

Corcept Therapeutics Incorporated (CORT) announced Q2 revenue of $256.1 million, significantly exceeding the FactSet estimate of $221.1 million. The company also projected full-year 2026 revenue to be between $1.1 billion and $1.2 billion, surpassing the FactSet estimate of $999.5 million. Additionally, Corcept Therapeutics reported …

Corcept (NASDAQ:CORT) Reports Bullish Q2 CY2026, Stock Jumps 17.4%

Corcept (NASDAQ:CORT) Reports Bullish Q2 CY2026, Stock Jumps 17.4% Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 31.7% year on year to $256.1 million. The company's full-year revenue guidance of $1.15 billion at the …

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics reported strong Q2 2026 results with revenue of $256.1 million, a 32% increase year-over-year, and raised its full-year 2026 revenue guidance to $1.1 – $1.2 billion. The growth was driven by robust sales of Korlym® and the successful launch of its new …

Is CTVA Stock Worth Buying After a Powerful Rally and Earnings Beat?

Corteva (CTVA) has seen a 32.7% year-to-date gain, fueled by a strong earnings beat and improved operating outlook. While the company's Q1 2026 operating earnings significantly surpassed expectations, its valuation trades at a premium compared to industry benchmarks and its historical median. Despite a …

Why Corteva's Seed and Crop Protection Engines Matter to Investors

The article discusses why Corteva's two main business segments, Seed and Crop Protection, are important to investors, especially with a planned separation in late 2026. It highlights the distinct earning drivers of each segment, their performance in Q1 2026, and the company's cost-saving measures. …

How Corteva's Innovation Pipeline Could Shape Its Next Growth Cycle

Corteva is leveraging technology to drive its next growth cycle, focusing on new crop protection products and seed innovations. The company aims to achieve $2 billion in new crop protection revenues by 2026 and expects its seed business to become royalty positive in the …

Corteva, Inc. $CTVA Shares Bought by Royal Bank of Canada

Royal Bank of Canada significantly increased its stake in Corteva, Inc. (NYSE:CTVA) by 202.1% in the first quarter, now owning 7,458,624 shares valued at over $624 million. Other institutional investors also adjusted their holdings in Corteva, with hedge funds and institutional investors owning 81.54% …

Corteva, Inc. $CTVA Stock Holdings Lowered by California State Teachers Retirement System

California State Teachers Retirement System reduced its holdings in Corteva, Inc. (CTVA) by 1.7% in the first quarter, selling 30,311 shares but still holding 1.80 million shares valued at about $150.8 million. Despite this reduction, analysts maintain a "Moderate Buy" rating with an average …

Corcept Therapeutics (NASDAQ:CORT) Releases Quarterly Earnings Results, Beats Expectations By $0.34 EPS

Corcept Therapeutics Inc. (CORT) released its unaudited quarterly earnings report for the period ended June 30, 2026, detailing financial performance, product developments, and ongoing legal matters. The company reported $544.6 million in cash and securities, with product revenue increasing significantly due to higher sales …

Corteva Inc (CTVA) Institutional Confidence

Corteva Inc (CTVA) has an institutional shareholding score of 7.00, placing it 28th out of 65 in the Chemicals industry. The institutional shareholding proportion recently increased by 0.29% to 89.59%. David G. Herro is the largest institutional shareholder, holding 17.40 million shares, which represents …

Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1

Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1 Let's dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season. Looking ahead, the branded pharmaceutical industry is positioned for tailwinds from advancements …

Corteva Number of Employees 2026 | Employee Count & Headcount Data

Corteva, Inc. (CTVA) had approximately 21,683 total employees worldwide as of March 2026, marking a 1.2% growth from 2023. The company is actively hiring, with 602 active job postings in 2026, though this represents a 41.0% decline from 2025. The workforce is primarily concentrated …

Corcept (CORT) Q2 Earnings: What To Expect

Corcept (CORT) Q2 Earnings: What To Expect Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Wednesday after market hours. Here's what to expect. Corcept missed analysts' revenue expectations last quarter, reporting revenues of $164.9 million, up 4.9% year on year. It …

Corteva, Inc. (CTVA) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Corteva, Inc. (CTVA) is expected to announce Q2 earnings of $2.24 per share, a 1.8% increase year-over-year, with revenues forecasted at $6.62 billion, up 2.6%. Despite these positive headline figures, the consensus EPS estimate has seen a significant 89.9% downward revision in the past …

Corteva, Inc. $CTVA Stock Holdings Lifted by Cetera Investment Advisers

Cetera Investment Advisers increased its stake in Corteva, Inc. (NYSE:CTVA) by 7.7% in the first quarter, now holding 228,580 shares valued at $19.13 million. Other institutional investors also acquired new positions in the company. Analysts have issued new price targets for Corteva, with a …

CORT|Corcept Therapeutics Inc|Price:91.090|Chg%:-4.270

Corcept Therapeutics Inc. (CORT) is a commercial-stage company focused on discovering and developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol's effects. The company markets Korlym for Cushing's syndrome and has a pipeline of selective cortisol modulators including relacorilant, dazucorilant, …

Corteva announces Q3 2026 distribution of R$ 0.15 per unit for BDR holders

Corteva has announced a Q3 2026 distribution of R$ 0.15 per unit for holders of its BDRs (ISIN BRC1TVBDR007). Shares will trade with entitlement through August 28, and payment is scheduled for September 21. This news brief was generated by Public Technologies (PUBT) using …

Why Corcept (CORT) Stock Is Down Today

Why Corcept (CORT) Stock Is Down Today What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 2.9% in the morning session after Wolfe Research downgraded the stock to 'Underperform' from 'Peerperform', citing valuation concerns. The firm set a price target of $50.00 per …

Corcept Therapeutics Inc (CORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article for Corcept Therapeutics Inc (CORT) on TradingKey discusses the company's revenue breakdown. However, it explicitly states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides current stock information, including …

CTVA|Corteva Inc|Price:89.250|Chg%:+0.490

This article provides a detailed company profile for Corteva Inc (CTVA), a global pure-play agriculture company specializing in seed and crop protection solutions. It includes financial data, market performance metrics like market cap and P/E ratio, and details on its business segments, key executives, …

Corteva, Inc. $CTVA Shares Sold by First Trust Advisors LP

First Trust Advisors LP significantly reduced its stake in Corteva, Inc. ($CTVA) by 43.8% in the first quarter, selling over 465,000 shares. Despite this, other institutional investors like Brighton Jones LLC and Woodline Partners LP increased their holdings. Wall Street analysts maintain a positive …

Corteva Inc (CTVA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Corteva Inc (CTVA), listing its major institutional holders, types of shareholders, and recent institutional shareholding trends. Key shareholders include Vanguard Capital Management, BlackRock, and State Street Investment Management, while investment advisors constitute the largest shareholder type. The …

Bank of Nova Scotia Sells 120,104 Shares of Corteva, Inc. $CTVA

Bank of Nova Scotia trimmed its stake in Corteva, Inc. (NYSE:CTVA) by 52.3% in the first quarter, selling 120,104 shares and reducing its holdings to 109,660 shares valued at $9.18 million. Meanwhile, other institutional investors have increased their positions in Corteva, and analysts maintain …

Wolfe Research downgrades Corcept stock on valuation concerns By Investing.com

Wolfe Research downgraded Corcept Therapeutics (NASDAQ:CORT) from Peerperform to Underperform with a $50 price target, citing valuation concerns despite strong initial sales for Lifyorli and recent regulatory successes. The firm believes the current stock price, which has risen significantly after FDA approval for ovarian …

Lombard Odier Asset Management Europe Ltd Has $13.90 Million Position in Corteva, Inc. $CTVA

Lombard Odier Asset Management Europe Ltd reduced its stake in Corteva, Inc. by 11.9% during the first quarter, holding shares valued at $13.90 million. Several other institutional investors also adjusted their positions in Corteva during the same period. The article also details recent analyst …

Corteva Inc (CTVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed breakdown of Corteva Inc.'s (CTVA) revenue by business segments and geographical regions. As of April 6 (updated), Corn contributes the largest share to its business revenue, followed by Herbicides, while North America accounts for over half of its regional …

Corcept Therapeutics (CORT) Lifted Earnings Outlook, Is The Stock Now Overvalued?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Corcept Therapeutics (CORT) has attracted fresh attention after a sharp improvement in its earnings outlook, with full year earnings estimates rising significantly and analyst sentiment turning more …

Corcept Therapeutics (CORT) Is Up 5.3% After Analysts Lift Full-Year Earnings Outlook Significantly

Recently, Corcept Therapeutics received an upgraded Zacks Rank of #2 (Buy) after analysts sharply raised their full-year earnings estimates, reflecting a much stronger profit outlook than previously expected. This improved earnings view has come alongside performance that has far outstripped the broader Medical sector …

Corcept Therapeutics Inc (CORT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Corcept Therapeutics Inc. (CORT), focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page displays various financial metrics for CORT, including its market …

Corteva, Inc. (NYSE:CTVA) to Issue Quarterly Dividend of $0.18

Corteva, Inc. (NYSE:CTVA) announced a quarterly dividend of $0.18 per share, payable on September 15th to shareholders of record on September 1st. The company has consistently raised its dividend for the past five years, supported by a low payout ratio of 20.5%. Analysts anticipate …